Every cancer is unique.
For patients with challenging cancers - those with a limited standard of care - understanding the unique attributes of their tumor is critical to identifying the best therapeutic options.
We built Valius for these patients.
We believe comprehensive, maximalist diagnostics should be the primary input to treating difficult cancers. Unlike traditional diagnostics, which report on only a small number of targets, Valius’s process is designed to assess every biological layer—DNA, RNA, and protein—and evaluate all therapeutic targets for each patient, regardless of tumor type, at every time point.
As a result, we regularly find actionable markers not identified by standard diagnostics.
Today, we’re excited to announce that we’ve raised $10M in new capital. The fundraise was led by 8VC and Basis Set Ventures, with participation from Define Ventures and Even One Ventures. Our team has worked with each of these investors for more than a decade, and we’re thrilled that they share our vision.
With this capital, we’ll continue invest in new diagnostic modalities and analytical approaches to serve our patients. This includes expanding our team of world-class scientists, bioinformaticians, and engineers, and spearheading clinical single-cell gene expression analysis, which will open unprecedented new avenues for assessing tumor behavior.
Dealing with a challenging cancer diagnosis is scary. By partnering with Valius, patients get rigorous science, deep partnership, and a "leave no stone unturned" approach. Armed with our insights, patients and their oncologists can think creatively about the best treatments for their unique cancer.
If you want to learn more about Valius, get in touch with us here or drop us a line at outreach@valiussciences.com.
